The report, published Thursday in the medical journal JAMA Ophthalmology, found that five out of 25,330 patients studied, or less than 0.02%, of those who took Ozempic and Wegovy, also known as GLP-1 drugs, developed non-arteritic anterior ischemic optic neuropathy, or NAION, a sudden loss of vision in one eye
Maxwell, Assistant Professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center (prior mentee of James Howe) Diversity, Equity & Inclusion Award- Udhayvir Singh Grewal, Clinical Assistant Professor, Department of Hematology and Oncology, Winship Cancer Institute of Emory University (prior mentee of Chandrikha Chandrasekharan) Neuroendocrine Tumor Research Foundation (NETRF) Symposium 2025, Boston, MA
If you can get to that which is difficult by the way I think your patients will really appreciate this. An additional PDT pearl Dr
It also lines up with the expected entry of additional weight loss products in 2027, including new options from Novo Nordisk and other manufacturers
Finally, very few studies have touched upon any negatives associated with the use of BPC 157 (having no known toxicity level), as well as no obvious conflicts in literature-based ideas being seen
.png.jpg)
